Theralink Technologies 

Theralink Technologies, Inc., headquartered in Golden, Colorado, is a commercial-stage enterprise specializing in precision medicine and the generation of crucial molecular data. The company is dedicated to advancing and bringing to market innovative cancer immunotherapy products. Utilizing its proprietary platform, which focuses on phosphoprotein and protein biomarkers, alongside its sophisticated laboratory-developed test (LDT) technology, Theralink addresses diverse aspects of oncology and pharmaceutical research. Through their specialized Theralink Reverse Phase Protein Array assays, they provide highly accurate oncology data. This information enables the biopharmaceutical industry and clinical oncologists to more precisely predict which patients will respond to, or be resistant to, both FDA-approved and investigational drug treatments. Ultimately, Theralink's diagnostic assays deliver vital, actionable insights that benefit physicians, patients, and biopharmaceutical companies operating within the field of cancer care. The company adopted its current name, Theralink Technologies, Inc., in September 2020, having previously operated as OncBioMune Pharmaceuticals, Inc.